Frontlight ResearchEarly access
WithdrawnPhase 2
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Key facts
- Who runs it
- Providence Health & Services
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Jul 2023
- Expected to end
- 1 Jul 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- GR-MD-02
- Placebo
- Pembrolizumab
- Record updated
- 6 June 2023
- Why it stopped
- Study withdrawn due to lack of supply of one of the investigational agents.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (20)Hide the full registry criteria
Who can take part
- Patients with unresectable or metastatic melanoma including unknown primary, mucosal or uveal melanomas. Histological confirmation of melanoma will be required by previous biopsy or cytology. Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression during or after platinum-containing chemotherapy are eligible. PD-L1 testing is not needed for OHN cancers
- Patients who have received anti-PD1 or anti-PD-L1 in the past are eligible if it has been at least 6 months since the last anti-PD-1 or PD-L1 dose, they meet all other eligibility criteria and progression of malignancy has been documented on imaging. Progression for this patient subset is defined as the appearance of one or more new metastatic sites, or a 5% or greater increase in the sum of diameter of target lesions or an unequivocal increase in non-target site. Treatment naïve melanoma patients are eligible
- Patients must be ≥ 18 years of age
- ECOG performance status of 0-2
- Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy
- No active bleeding
- Anticipated lifespan greater than 12 weeks
- Patients must sign a study-specific consent document
Who cannot take part
- Patients who have previously received a galectin antagonist
- Patients with untreated brain metastases. Patients with treated brain metastases who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible
- Patients requiring other systemic oncologic therapy, including experimental therapies
- Need for steroids at greater than physiologic replacement doses. Inhaled corticosteroids are acceptable
- Inability to give informed consent and comply with the protocol. Patients must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy
- Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo (see Appendix C)
- Patients with history of autoimmune colitis
- Patients with active infection requiring antibiotics
- Any medical condition that in the opinion of the Principal Investigator would compromise the safety or conduct of the study procedures
- Unresolved immune-mediated pneumonitis, diarrhea, elevation of hepatocellular enzymes or other toxicities requiring greater than physiological replacement doses of steroids
- Laboratory exclusions (to be performed within 28 days of enrollment):; WBC < 3.0 x 109/L; Hgb < 9.0 g/dL; AST or ALT > 1.5 times ULN; Total bilirubin > 1.9 g/dL, unless due to Gilbert's Syndrome. If Gilbert's Syndrome is present by clinical history, then direct bilirubin must by < 3.0 g/dl; Known history of HIV; Known history of Hepatitis B; Known history of Hepatitis C; INR > 1.5x ULN
- Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus
Where in United States
- Portland Providence Medical CenterPortland, United States
About the trial
What the trial wants to find out
The purpose of this study is to test the safety \& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.
The 2 groups in the trial
- GR-MD-02 + pembrolizumabTreatment being tested
4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
Treatment: GR-MD-02 and Pembrolizumab
- Pembrolizumab MonotherapyPlacebo, for comparison
4 mg/kg placebo in combination with standard pembrolizumab treatment.
Treatment: Placebo and Pembrolizumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
- Record updated
- 6 June 2023